Let me be honest with you from the start: I am not here to tell you that mushrooms will fix your brain. Your brain does not need fixing. But if you have spent years navigating the world with an ADHD or autistic brain, you already know that the tools available to you are… limited. And you have probably noticed that the psychedelic research boom happening right now has a glaring blind spot: almost none of it includes people like you.
So let’s talk about what we actually know, what we don’t, and why this conversation matters more than most researchers seem to realize.
The Default Mode Network: Where This Gets Interesting
To understand why psilocybin research matters for neurodivergent brains, you need to understand the default mode network, or DMN. Think of it as the brain’s background narrator — the network that activates when you are not focused on external tasks. It is responsible for self-referential thinking, mind-wandering, mental time travel, and the construction of your sense of self.
But critically… the DMN does not work the same way in neurodivergent brains.
In ADHD, the DMN has a tendency to intrude when it should be quiet. You know that experience of sitting down to work and suddenly finding yourself replaying a conversation from 2019? That is your DMN refusing to deactivate when your task-positive network should be running the show. Research from Castellanos and colleagues has consistently shown that ADHD involves weaker anticorrelation between the DMN and task-positive networks — essentially, they bleed into each other instead of taking clean turns.
In autism, the picture is different but equally significant. Multiple neuroimaging studies have found reduced functional connectivity within the DMN, along with atypical patterns of connectivity between the DMN and other networks. This may relate to differences in self-referential processing, theory of mind, and the way autistic people construct internal narratives about themselves and others.
Now enter psilocybin. One of the most robust findings in psychedelic neuroscience is that psilocybin temporarily disrupts the DMN. It does not just quiet it — it fundamentally reorganizes communication patterns across the brain, allowing networks that normally operate independently to start cross-talking in novel ways. Researchers at Imperial College London have described this as an increase in “entropy” — more randomness, more flexibility, less rigid patterning.
So what happens when you modulate a network that is already operating differently?
Unfortunately, we don’t have a clear answer. Apart from anecdotal evidence, and who in their right minds would post about psychedelic mushrooms online? The risk to reward ratio is a nightmare. The existing research on how psilocybin affects the brain was conducted almost entirely on neurotypical participants. We are extrapolating from brains that do not work like ours, and calling it evidence, when it literally, like everything else, describes a neurotypical reality that is as foreign to us as breathing water.
Even so, the theoretical framework is compelling. If ADHD involves a DMN that will not shut up, and psilocybin temporarily dissolves the DMN’s dominance, the implications are worth studying. If autism involves rigid connectivity patterns, and psilocybin increases neural flexibility, that is worth studying too. But “worth studying” and “proven to help” are very different claims, and I am not going to pretend otherwise.
ADHD: The Dopamine Problem and the Microdosing Question
If you have ADHD, you are intimately familiar with the dopamine paradox. Your brain does not produce enough dopamine to sustain attention on tasks that are not intrinsically rewarding, so you take stimulant medication that floods your dopamine system — medication that would wire up a neurotypical person but just brings you to baseline. It works. For many people, it works well. But the side effects are real, the long-term trajectory is uncertain, and there is a restless dissatisfaction in the ADHD community about being dependent on a controlled substance that many people feel reduces their creativity and emotional range.
Enter microdosing. Sub-perceptual doses of psilocybin — typically one-tenth to one-twentieth of a full dose — taken on a structured schedule like the Fadiman protocol (one day on, two days off). The microdosing community has been growing for years, and neurodivergent people are disproportionately represented in it.
Why? Because the anecdotal reports are exactly what ADHD brains are hungry for: improved focus without the flatness of stimulants, better emotional regulation, increased motivation for boring tasks, and a sense of “flow” that feels organic rather than chemically forced.
But here is where I have to pump the brakes. The clinical evidence for microdosing and ADHD is thin. Not nonexistent — but thin. A 2021 survey study by Hutten and colleagues found that self-reported ADHD symptoms were among the most common reasons people microdose, and that many participants reported subjective improvements. Petranker et al. published similar findings. But survey data is self-selected and uncontrolled. People who microdose and feel better report it. People who microdose and feel nothing, or feel worse, are less likely to show up in the data.
The controlled trials that do exist on microdosing — and there are now several — have generally found that the effects are small and inconsistent, with expectancy (placebo) playing a significant role. The 2021 Imperial College self-blinding study by Szigeti et al. was particularly deflating for microdosing advocates: improvements in wellbeing were real but could not be distinguished from placebo.
Does that mean microdosing does not work for ADHD? No. It means we do not know yet. It means the signal is noisy and the research has not been designed to detect ADHD-specific effects. The trials are not recruiting ADHD participants specifically, not measuring executive function with ADHD-appropriate instruments, and not controlling for stimulant medication use. The study that needs to exist — a randomized controlled trial of psilocybin microdosing in adults with ADHD, measuring working memory, sustained attention, and task-switching — has not been done.
For people exploring natural approaches to focus and ADHD management, the options remain a patchwork of compounds with varying levels of evidence. Lion’s mane mushroom has more clinical support for cognitive function than psilocybin microdosing currently does, though the mechanisms are completely different.
What I will say is this: if you have ADHD and you are microdosing, you are not crazy or irresponsible. You are running an experiment on yourself because the medical establishment has not gotten around to running it for you. Just be honest with yourself about what you know and what you are guessing.
Autism: Neural Flexibility, Pattern Recognition, and the Emotional Processing Gap
The autism-psilocybin conversation is different from the ADHD one, and in some ways more interesting.
One of the frameworks that has gained traction in autism neuroscience is the idea of reduced neural flexibility — the tendency for autistic brains to settle into strong, stable patterns of connectivity that resist change. This is not inherently bad. It is part of what gives autistic people their capacity for deep focus, pattern recognition, systematic thinking, and expertise development. But it may also contribute to the rigidity that makes transitions difficult, the distress of disrupted routines, and the challenge of adapting to novel social situations.
Psilocybin, as we discussed, increases neural entropy. It temporarily loosens the brain’s habitual patterns and allows new connections to form. The theoretical argument for psilocybin in autism is that this temporary increase in flexibility might help “unstick” patterns that have become sources of suffering — not the useful patterns of deep expertise, but the painful ones: rigid anxiety loops, compulsive behaviors driven by distress, difficulty with emotional processing.
And here, there is actual research. Small, early-stage, but real.
Imperial College London conducted a study on psilocybin and psychological flexibility that, while not specifically targeting autistic participants, measured outcomes that are directly relevant to autistic experience. Increased psychological flexibility — the ability to adapt to changing circumstances without excessive distress — is one of the most consistent findings in psilocybin research, and it is one of the areas where many autistic people report the greatest difficulty.
A 2023 study by Benz and colleagues specifically surveyed autistic adults who had used psychedelics. Participants reported increased social connectedness, reduced social anxiety, greater emotional awareness, and a sense of being more comfortable in their own skin. These are not small claims — for many autistic adults, social anxiety and emotional disconnection are not just inconveniences but primary sources of suffering.
Then there is the alexithymia angle, and this one is particularly compelling.
Alexithymia — difficulty identifying and describing one’s own emotions — is strikingly common in autism. Estimates range from 50% to 85% of autistic adults, compared to roughly 10% of the general population. It is not that autistic people do not have emotions. It is that the internal labeling system is unreliable. You feel something, but you cannot name it, cannot locate it, cannot tell if it is anger or hunger or sadness or overstimulation.
Psilocybin appears to do something remarkable with emotional processing. Multiple studies have shown increased emotional awareness, greater access to feelings that were previously blocked or muffled, and what participants describe as a kind of emotional “thawing.” For someone with alexithymia, this could be genuinely transformative — not in a dramatic “I can suddenly feel everything” way, but in a gradual recalibration of the connection between emotional experience and conscious awareness.
But again: “could be” is doing a lot of work in that sentence. The research specifically examining psilocybin’s effects on alexithymia in autistic adults is virtually nonexistent. We are connecting dots between separate bodies of literature and hoping the picture holds up when someone finally studies it directly.
Microdosing: Why Neurodivergent People Keep Showing Up
The Fadiman protocol — one day on, two days off, repeating — has become something of a standard in the microdosing world, though variations abound. (Paul Stamets advocates a different schedule with the addition of lion’s mane and niacin.) The dose is sub-perceptual, meaning you should not feel “high” or experience any visual or cognitive distortion. The idea is that the neuroplasticity-promoting effects of psilocybin operate below the threshold of conscious psychedelic experience.
Microdosing protocols have attracted a disproportionate number of neurodivergent people, and this is not an accident. The appeal makes sense when you consider what neurodivergent people are typically looking for: not a trip, not an altered state, but a subtle recalibration. Better executive function. Less sensory overwhelm. Fewer meltdowns. More emotional access. The promise of microdosing is that you can get the neuroplastic benefits of psilocybin without disrupting your ability to function — and for people whose daily functioning already requires enormous effort, that matters.
Community surveys and Reddit forums (which, let’s be real, are where most of the actual user data lives right now) consistently report that neurodivergent microdosers describe benefits in three main areas: emotional regulation, cognitive flexibility, and sensory processing. Some report that microdosing reduces sensory overwhelm, which is counterintuitive but consistent across enough reports to be worth noting. Others describe improved ability to handle transitions and unexpected changes. Many describe feeling “more like themselves” — a phrase that shows up with remarkable frequency.
But anecdotes are not evidence, no matter how consistent they are. Confirmation bias is real. Community self-selection is real. The placebo response is real and powerful. I am not dismissing these reports — they matter, they should be studied, and they represent real human experience. But I am also not going to tell you they prove anything, because they do not.
Safety: What Neurodivergent Brains Need to Know
This is the section that most articles skip or treat as an afterthought. It should not be.
Sensory sensitivity. If you are autistic and have significant sensory processing differences, a full psilocybin experience could be intensely overwhelming. Psilocybin amplifies sensory input — colors become more vivid, sounds become more textured, tactile sensations intensify. For someone whose sensory system is already running hot, this amplification could tip the experience from profound to unbearable. Set and setting are not optional considerations — they are critical safety measures, especially for sensory-sensitive individuals. A quiet, controlled environment with a trusted person present is the minimum.
Anxiety and demand avoidance. Many autistic and ADHD people experience high baseline anxiety. Psilocybin can increase anxiety during the onset period, and for some people, this escalates into a difficult experience. The “surrender” advice that psychedelic guides often give — just let go, stop resisting — can be genuinely unhelpful for people whose nervous systems are wired to resist perceived threats. This does not mean psilocybin is contraindicated, but it means preparation and support need to be adapted, not copy-pasted from neurotypical protocols.
Medication interactions. This is critical. Many neurodivergent people take psychiatric medication, and psilocybin interacts with several classes.
SSRIs and SNRIs are the biggest concern. These medications work on the serotonin system, and so does psilocybin. At best, SSRIs will blunt the effects of psilocybin and you will feel nothing. At worst, combining serotonergic substances carries a risk of serotonin syndrome, which is a medical emergency. The relationship between SSRIs and psilocybin is complex and not fully understood, but the general guidance is clear: do not combine them without medical supervision, and never abruptly stop an SSRI to take psilocybin. SSRI withdrawal is its own nightmare.
Stimulant medications (Adderall, Ritalin, Vyvanse) are a different story. They work primarily on dopamine and norepinephrine, not serotonin, so the serotonin syndrome risk is lower. But the interaction is still understudied, and stimulants can increase anxiety and cardiovascular stress — adding psilocybin on top of that baseline is an unknown variable.
Lithium is a hard no. Case reports of seizures with psychedelics and lithium have been documented, and this combination should be treated as dangerous until proven otherwise.
Masking and the psychedelic experience. Here is something the research community has not grappled with at all: many autistic people spend their entire lives masking — performing a version of themselves that is legible to neurotypical people. Psilocybin tends to dissolve masks. It strips away the performed self and exposes whatever is underneath. For some autistic people, this is profoundly liberating — finally being allowed to just be, without the exhausting performance. For others, it is terrifying, because the mask is not just a social tool; it is a protective structure, and removing it without adequate support can feel like freefall.
The Research Gap No One Talks About
Here is what frustrates me most about the current state of psychedelic research: the clinical trials are systematically excluding neurodivergent participants.
Most psilocybin trials screen out people with comorbid psychiatric diagnoses, which disproportionately excludes autistic and ADHD adults. Most exclude people on psychiatric medication, which again disproportionately excludes neurodivergent people. Some explicitly exclude autism and ADHD diagnoses from their inclusion criteria.
The result is that the growing body of “evidence” for psilocybin’s therapeutic potential is built on a foundation that does not include 15-20% of the adult population. When researchers say “psilocybin is safe and effective for treatment-resistant depression,” they are saying it is safe and effective for neurotypical people with treatment-resistant depression. Whether those findings translate to neurodivergent brains is an open question.
This is not just an academic concern. Neurodivergent people have higher rates of depression, anxiety, PTSD, and substance use disorders than the general population. We are the people who arguably need new therapeutic tools the most, and we are being excluded from the research that might provide them.
Some researchers are starting to notice this gap. There are early-stage studies specifically examining psilocybin in autistic adults, and a growing number of researchers are calling for neurodivergent-inclusive trial design. But “starting to notice” is not the same as “actively fixing,” and the timeline for dedicated clinical trials is measured in years, not months.
The Self-Medication Reality
Let’s address the elephant in the room: many neurodivergent people are not waiting for the research. They are already using psilocybin — microdosing, macrodosing, or both — and making decisions based on their own experience, community knowledge, and the limited evidence available.
This is not reckless behavior. It is a rational response to a system that has failed to study their needs while simultaneously limiting their access to alternatives. When your options are “take the stimulant that flattens your personality” or “take the SSRI that kills your libido and emotions” or “just try harder,” experimentation with something that the available evidence suggests is physiologically safe starts to look less like risk-taking and more like self-advocacy.
That said, self-medication without information is still risky. If you are going to do this — and I am not telling you to, but I am also not telling you not to — do it with as much knowledge as possible. Understand what you are taking, how it interacts with your medications, what the dose range looks like, and what environments and support structures will keep you safe.
Where We Stand
The honest summary is this:
There is strong theoretical reason to believe that psilocybin could be uniquely relevant to neurodivergent brains. The DMN modulation, the neural flexibility, the emotional processing enhancement, the pattern disruption — these are not random effects. They map directly onto areas where neurodivergent people experience the most difficulty.
The anecdotal evidence is consistent and growing. Too many neurodivergent people report similar benefits for it to be pure noise.
The clinical evidence is almost nonexistent, specifically for neurodivergent populations. The studies that do exist are small, survey-based, and not designed to test the specific claims being made.
The research community is failing neurodivergent people by excluding them from trials and then implicitly extending their findings to populations they did not study.
And in the gap between the promising theory and the missing evidence, real people are making real decisions about their own brains, as they have always done.
What I want — what I think most of us want — is not hype. It is not another miracle cure narrative. It is honest, rigorous research that actually includes us. Research that asks the right questions: not “does psilocybin work for depression?” but “does psilocybin work differently in brains that are already wired differently?” Not “is microdosing effective?” but “what does microdosing do to a dopamine system that is already running at a deficit?”
Until that research exists, we are left with theory, anecdote, and our own judgment. For neurodivergent people, that is not a new situation. We have always had to be our own researchers, our own advocates, our own experts on what works for brains that the medical establishment was not designed to understand.
The least we can do is be honest about where the evidence stops and the hope begins.
This article is for informational purposes only. It is not medical advice. If you are considering psilocybin use, consult a healthcare provider who understands both psychedelic medicine and neurodivergent neurophysiology — and if you cannot find one who understands both, please at least find one who is willing to learn.
